证券代码：002173 证券简称：创新医疗 公告编号：2024-026 关于为鸿润医药提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次担保情况概述 创新医疗管理股份有限公司（以下简称"公司"）子公司浙江鸿润医药有限 公司（以下简称"鸿润医药"）因生产经营需要，拟向招商银行股份有限公司绍 兴诸暨支行（以下简称"招商银行诸暨支行"）在人民币 800 万元的授信额度内 申请贷款，贷款期限为一年。公司于 2024 年 5 月 15 日召开的第六届董事会 2024 年第四次临时会议审议通过了《关于为鸿润医药提供担保的议案》，同意公司为 鸿润医药在 800 万元授信额度内向招商银行诸暨支行申请贷款提供担保。 1 / 3 创新医疗管理股份有限公司 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 1 号—主板上市公司规范运作》等法律法规和规范性文件及公司《章程》 的规定，上述担保事项无需提交公司股东大会审议。 二、被担保人基本情况 1、公司名称：浙江鸿润医药有限公司 6、经营范围：许可项目：药品批发；药品零售；第三类医疗器 ...

证券代码：002173 证券简称：创新医疗 公告编号：2024-024 创新医疗管理股份有限公司 关于持股 5%以上股东一致行动人减持股份的预披露公告 持股5%以上股东上海瑞鑫融资租赁有限公司及一致行动人上海岩衡投资管 理合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 上海岩衡投资管理合伙企业（有限合伙）（以下简称"上海岩衡"）持有创新 医疗管理股份有限公司（以下简称"公司"）股份 8,674,729 股，占公司总股本 的 1.9658%，计划在本公告披露之日起 15 个交易日后的三个月内以集中竞价交 易、大宗交易方式减持本公司股份，减持数量不超过 8,674,729 股，即不超过公 司总股本的 1.9658%。上海岩衡与持有公司股份 33,720,222 股的股东上海瑞鑫 融资租赁有限公司（以下简称"上海瑞鑫"）互为一致行动人。 注：公司"总股本"有效计算基数为 441,284,352 股，即当前总股本 449,043,052 股剔除公司目前回购专用证券账户中的 7,758 ...

上海市锦天城律师事务所 关于创新医疗管理股份有限公司 2023 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于创新医疗管理股份有限公司 2023 年年度股东大会的 法律意见书 致：创新医疗管理股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受创新医疗管理股份有限公 司（以下简称"公司"）委托，就公司召开 2023 年年度股东大会（以下简称"本次 股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《上市公司股东大会规则》等法律、法规、规章和其他规范性文件以及《创新医 疗管理股份有限公司章程》（以下简称"《公司章程》"）的有关规定，出具本法 律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必 ...

证券代码：002173 证券简称：创新医疗 公告编号：2024-022 创新医疗管理股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况： 1、会议召开时间： （1）现场会议时间：2024年5月9日（星期四）14:00； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2024年5 月9日9:15—9:25，9:30—11:30，13:00—15:00；通过深圳证券交易所互联网投 票系统（http://wltp.cninfo.com.cn）投票时间为9:15至15:00。 2、会议地点：浙江省诸暨市山下湖珍珠工业园区公司五楼会议室。 3、会议召开方式：以现场表决和网络投票相结合的方式召开。 4、会议召集人：公司董事会。 5、会议主持人：陈海军董事长。 6、本次股东大会的召集、召开符合《公司法》、《上市公司股东大会规则》 等法律、行政法规、部门规章、规范性 ...

证券代码：002173 证券简称：创新医疗 公告编号：2024-023 创新医疗管理股份有限公司 关于注销公司已回购股份通知债权人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、通知债权人的原由 创新医疗管理股份有限公司（以下简称"公司"）2024 年 5 月 9 日召开的 2023 年年度股东大会审议通过了《关于注销公司已回购股份并减少注册资本的 议案》，同意减少注册资本。具体内容详见 2024 年 5 月 10 日公司在巨潮资讯网 （www.cninfo.com.cn）上披露的相关公告。 公司于2021年1月19日召开了第六届董事会第三次会议，审议通过了《关于 回购部分社会公众股份的议案》，决定以自有资金通过集中竞价的方式回购公司 股份，用于维护公司价值及股东权益所必需。公司于2021年1月25日至2021年4 月18日期间，通过回购专用证券账户回购了公司股份7,758,700股，占目前公司 总股本的比例为1.73%，成交金额为48,396,390.66元。上述已回购股份的后续安 排为在披露回购结果公告后三年内完成减持，若未能在相关法律法规规定 ...

创新医疗管理股份有限公司 关于召开 2023 年度网上业绩说明会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 创新医疗管理股份有限公司（以下简称"公司"）已于 2024 年 4 月 13 日在 巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2023 年年度报告》及《2023 年年度报告摘要》。 为便于广大投资者进一步了解公司 2023 年年度经营情况，公司定于 2024 年 5 月 6 日（星期一）15:00 至 17:00 在"约调研"小程序举行 2023 年度网上 业绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者可登陆"约 调研"小程序参与互动交流。为广泛听取投资者的意见和建议，提前向投资者征 集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"约调研"； 参与方式二：微信扫一扫以下二维码： 证券代码：002173 证券简称：创新医疗 公告编号：2024-021 员会有调整） 敬请广大投资者积极参与。 特此公告。 创新医疗管理股份有限公司 董 事 会 2024 年 4 月 27 日 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 201,344,535.99, a decrease of 1.40% compared to CNY 204,206,456.23 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 2,977,863.39, representing a decline of 37.87% from a loss of CNY 2,159,886.00 in the previous year[4] - The company's net profit excluding non-recurring gains and losses was a loss of CNY 2,708,735.09, a decline of 876.63% from a profit of CNY 277,355.34 in the same period last year[4] - The weighted average return on equity was -0.16%, compared to -0.11% in the previous year, indicating a slight deterioration in profitability[4] - The company reported non-recurring losses totaling CNY 269,128.30 for the quarter, primarily due to other operating expenses[6] - The company's net loss for Q1 2024 was CNY 1,307,215,574.97, slightly increasing from CNY 1,304,237,711.58 in the previous quarter[13] - Operating profit was reported at -¥2,112,325.21, a decline from -¥224,986.20 in the previous period, reflecting a significant deterioration in operational performance[16] - Total revenue from operating activities was ¥182,904,706.98, down from ¥222,244,830.87, representing a decrease of about 17.7%[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 17,663,752.00, a significant decrease of 242.76% compared to a positive cash flow of CNY 12,372,882.62 in the same period last year[4] - The company's cash and cash equivalents at the end of Q1 2024 were CNY 543,823,060.69, a decrease of 3.4% from CNY 563,083,485.71 at the beginning of the quarter[12] - The net cash flow from operating activities was -¥17,663,752.00, contrasting with a positive cash flow of ¥12,372,882.62 in the previous period[19] - Cash and cash equivalents at the end of the period totaled ¥529,951,281.78, an increase from ¥249,019,635.01 at the beginning of the period, showing a net increase of ¥280,931,646.77[19] - The company generated ¥304,563,287.72 from investment activities, significantly higher than the previous period's cash inflow of ¥215,000.00[19] - The net cash flow from financing activities was ¥10,452,995.48, compared to a negative cash flow of -¥6,065,486.72 in the previous period, indicating improved financing conditions[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,264,284,369.08, a decrease of 0.75% from CNY 2,281,472,772.53 at the end of the previous year[5] - The equity attributable to shareholders was CNY 1,867,174,252.09, down 0.16% from CNY 1,870,152,115.48 at the end of the previous year[5] - The total assets of the company at the end of Q1 2024 were CNY 2,264,284,369.08, a decrease of 0.8% from CNY 2,281,472,772.53 at the beginning of the quarter[13] - The total liabilities decreased to CNY 396,176,814.89, down 3.4% from CNY 410,385,658.35 at the beginning of the quarter[12] - The company's inventory decreased to CNY 37,726,419.22, down 9.9% from CNY 41,805,047.04 at the beginning of the quarter[12] - The company’s long-term equity investments decreased to CNY 14,345,628.32, down from CNY 15,219,218.88 at the beginning of the quarter, reflecting a decline of 5.7%[12] Earnings Per Share - The basic and diluted earnings per share were both negative CNY 0.0067, down 39.58% from negative CNY 0.0048 in the previous year[4] - Basic and diluted earnings per share were both reported at -¥0.0067, worsening from -¥0.0048 in the previous period[16] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[4] - The company has not undergone an audit for the first quarter report, which may affect the reliability of the financial data presented[21] - The company is set to implement new accounting standards starting in 2024, which may impact future financial reporting[20]

创新医疗管理股份有限公司 关于募集资金专户销户完成的公告 证券代码：002173 证券简称：创新医疗 公告编号：2024-019 创新医疗管理股份有限公司 董 事 会 2024 年 4 月 17 日 1 / 1 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 创新医疗管理股份有限公司（以下简称"公司"）于2024年4月11日召开了 第六届董事会第五次会议，审议通过了《关于募集资金使用完毕及注销募集资金 账户的议案》，同意对目前尚存的募集资金专户（海宁康华医院有限公司，中国 工商银行股份有限公司海宁支行，账号：1204085029201504833）进行销户处理。 具体内容详见公司2024年4月13日披露于《中国证券报》、《证券时报》、《证 券日报》、《上海证券报》及巨潮资讯网（www.cninfo.com.cn）的相关公告。 公司已于2024年4月16日完成了上述募集资金专户注销手续。公司、海宁康 华医院有限公司与保荐机构、相关银行签署的《募集资金四方监管协议》相应终 止。 特此公告。 ...

Business Transformation - The company reported a significant transformation from a single business model focused on pearl farming to a dual business model that includes high-quality medical services as its main operation[20]. - The company has expanded its operations to include hospital management consulting services, investment in the healthcare sector, and research and development of medical devices and pharmaceuticals[21]. - The company has established three subsidiaries: Jianhua Hospital, Kanghua Hospital, and Fuyuyuan Hospital, enhancing its presence in the healthcare industry[20]. - The company has committed to providing high-quality medical services as part of its strategic transformation[20]. Financial Performance - The company's operating revenue for 2023 was ¥805,585,526.56, representing a 13.51% increase compared to ¥709,698,070.78 in 2022[22]. - The net profit attributable to shareholders improved to -¥34,287,743.35 in 2023, a 53.30% reduction from -¥73,697,199.07 in 2022[22]. - The net cash flow from operating activities was ¥11,030,985.78, a significant turnaround from -¥24,445,528.60 in the previous year, marking a 145.12% increase[22]. - The basic earnings per share improved to -¥0.08, a 50.00% increase from -¥0.17 in 2022[22]. - Total assets at the end of 2023 were ¥2,281,472,772.53, down 2.48% from ¥2,339,662,759.53 at the end of 2022[22]. - The company reported a net asset attributable to shareholders of ¥1,870,152,115.48 at the end of 2023, reflecting a decrease of 1.78% from ¥1,904,313,052.88 in 2022[22]. Operational Challenges - The company emphasizes the importance of risk awareness in its future operational outlook, highlighting potential challenges[4]. - The company acknowledged uncertainty regarding its ability to continue as a going concern, as indicated by negative net profits over the last three years[24]. - The net profit attributable to shareholders for Q4 2023 was -¥20,072,977.57, indicating ongoing challenges in profitability[28]. - Non-operating losses totaled -¥6,285,167.14 for 2023, compared to a gain of ¥10,508,833.18 in 2022[29]. Market and Industry Trends - The healthcare market is projected to expand due to increasing healthcare demands driven by an aging population and heightened public health awareness[84]. - The company aims to enhance its management level and service quality through refined management practices and internal control systems[37]. - The company is committed to expanding its market presence and improving its competitive advantage through strategic partnerships and community health service networks[40]. Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management[4]. - The company maintained a fully independent operational structure, with no interference from the controlling shareholder in business, personnel, assets, or financial matters[98]. - The company’s governance practices align with the requirements set forth by the China Securities Regulatory Commission, with no significant discrepancies noted[97]. - The company has implemented a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management[96]. Shareholder Relations - The company held 1 annual general meeting and 3 extraordinary general meetings during the reporting period, ensuring equal treatment of all shareholders, especially minority shareholders[95]. - The participation rate of investors in the 2023 first extraordinary general meeting was 30.23%, while the participation rate for the 2022 annual general meeting was 34.98%[101]. - The company’s management team includes experienced professionals, with the chairman holding 22,225,300 shares, reflecting significant personal investment in the company[102]. Employee Management - The total number of employees at the end of the reporting period was 2,749, with 686 doctors and 959 nurses[125]. - The company has implemented a performance-based salary incentive system to motivate employees[126]. - The company plans to continue internal and external training for medical staff to improve service quality[127]. Environmental Responsibility - The company integrates ecological and environmental protection into its development strategy, focusing on minimizing hospital waste and optimizing resource utilization[139]. - The company has committed to improving hospital environments and patient satisfaction through enhanced waste management and environmental practices[139]. Legal and Regulatory Matters - The company reported a provision of RMB 130.42 million for a legal dispute related to a financing lease contract, with RMB 30.32 million recognized as other income in the current period[148]. - The company is currently involved in ongoing litigation related to financing lease agreements, with no final judgment reached as of now[154]. - The company has taken effective measures to rectify issues pointed out in the warning letter from the regulatory authority[156]. Strategic Acquisitions and Investments - The company has completed two strategic acquisitions in the past year, enhancing its product portfolio and market presence[106]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $100 million allocated for potential mergers[112]. Future Outlook - Future outlook indicates a projected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[109]. - The company expects a revenue growth of 10% for the next fiscal year, projecting revenues to reach approximately 1.32 billion RMB[115].

创新医疗管理股份有限公司 鉴证报告 创新医疗管理股份有限公司全体股东： 我们接受委托，对后附的创新医疗管理股份有限公司（以下简 称"贵公司"） 2023年度募集资金存放与使用情况专项报告（以下简 称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 贵公司董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》以及 《深圳证券交易所上市公司自律监管指南第2号——公告格式》的相 关规定编制募集资金专项报告。这种责任包括设计、执行和维护与 募集资金专项报告编制相关的内部控制，确保募集资金专项报告真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第3101号——历 史财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证业务。 该准则要求我们遵守职业道德规范，计划和实施鉴证工作 ...